A Phase 2 interventional study of Ruconest in Confirmed Coronavirus Disease, sponsored by Pharming Technologies B.V.. Completed at 4 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-02-16.
Sponsored by Pharming Technologies B.V. (part of Pharming Group N.V.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to evaluate if adding rhC1-INH to standard of care (SOC) in patients admitted for stage II COVID-19 infection may reduce the risk of disease progression, i.e. ALI requiring mechanical ventilation, or increase the chance of a faster clinical improvement compared to SOC alone.
Patients fulfilling all eligibility criteria will be randomized in a 2:1 ratio in an open-label controlled design to treatment with rhC1-INH in addition to SOC or SOC only starting on day 0. The first rhC1-INH treatment will be administered on the same day and continued for a total of 4 days.
Pharming Technologies B.V. is the lead sponsor of 22 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive (150 U/ml) of Ruconest at a 50 U/kg dose (max dose of 4200 U) as a slow intravenous injection via a peripheral every 12 hours; for 4 days. A total of 8 doses will be administered.
Drug: Ruconest
SOC
Drug: Ruconest
Patients will be randomized to Ruconest or Standard of Care
Also known as: SOC
Number of Participants With Each Score on WHO 7-point Outcome Scale at Day 7
The disease severity on the 7-point WHO Ordinal Scale on Day 7 was the primary objective of this study. This endpoint had been suggested by the WHO for clinical trials in patients with Covid-19. The ordinal scale measures illness severity over time. The higher score, the worst outcome: meaning score 1, no limitation in activities and score 7, death.
Time frame: Assessed on each day after enrollment (worst status) with the use of the WHO Ordinal Scale and the score on day 7 will be analyzed stratified by its baseline value
Time to Clinical Improvement
Time from randomization to an improvement of (at least) two (score) points on the seven-category WHO Ordinal Scale or live discharge from hospital whichever came first within 14 days after enrollment
Time frame: Daily until day 14
Invasive (Mechanical) or Non-invasive Ventilation
Admission to ICU with invasive or non-invasive ventilation will be assessed.
Time frame: Daily until day 14.
Number of Days Hospitalized
Amount of days the patient is hospitalized during participation in the study.
Time frame: between D0 and D90
Participants were randomized to two parallel groups in a 2:1 ratio to receive either rhC1INH (intervention) in addition to standard of care (SOC) or SOC treatment (control). Randomization was stratified by the study site before inclusion using randomly permuted block sizes of four.
| Milestone | Ruconest | Standard of Care |
|---|---|---|
| Started | 27 | 11 |
| Completed | 24 | 7 |
| Not completed | 3 | 4 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Death | 0 | 1 |
The disease severity on the 7-point WHO Ordinal Scale on Day 7 was the primary objective of this study. This endpoint had been suggested by the WHO for clinical trials in patients with Covid-19. The ordinal scale measures illness severity over time. The higher score, the worst outcome: meaning score 1, no limitation in activities and score 7, death.
| Participants | Ruconest | Standard of Care |
|---|---|---|
| WHO ordinal scale 1 | 6 | 0 |
| WHO ordinal scale 2 | 20 | 8 |
| WHO ordinal scale 3 | 0 | 0 |
| WHO ordinal scale 4 | 1 | 0 |
| WHO ordinal scale 5 | 0 | 1 |
| WHO ordinal scale 6 | 0 | 2 |
Time from randomization to an improvement of (at least) two (score) points on the seven-category WHO Ordinal Scale or live discharge from hospital whichever came first within 14 days after enrollment
| days | Ruconest | Standard of Care |
|---|---|---|
| Time to Clinical Improvement | 3.32 ± 0.32 | 4.91 ± 1.43 |
Admission to ICU with invasive or non-invasive ventilation will be assessed.
| Participants | Ruconest | Standard of Care |
|---|---|---|
| Invasive (mechanical) ventilation | 0 | 2 |
| Non-invasive ventilation | 12 | 7 |
Amount of days the patient is hospitalized during participation in the study.
| days | Ruconest | Standard of Care |
|---|---|---|
| Number of Days Hospitalized | 5.38 ± 1.76 | 11.27 ± 16.01 |
Collected over From signing off ICF till 90 days follow-up period Adverse event date were collected.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruconest | 0/27 (0%) | 3/27 (11.1%) | 23/27 (85.2%) |
| Standard of Care | 1/11 (9.1%) | 2/11 (18.2%) | 11/11 (100%) |
| Event | Ruconest | Standard of Care |
|---|---|---|
| Blood beta-D-glucan increasedInvestigations | 0/27 | 1/11 |
| EncephalopathyNervous system disorders | 0/27 | 1/11 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 0/27 | 1/11 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/27 | 1/11 |
| Respiratory failure [Death]Respiratory, thoracic and mediastinal disorders | 0/27 | 1/11 |
| HypotensionVascular disorders | 0/27 | 1/11 |
| ShockVascular disorders | 0/27 | 1/11 |
| HyperglycemiaMetabolism and nutrition disorders | 2/27 | 0/11 |
| LeukocytosisBlood and lymphatic system disorders | 1/27 | 0/11 |
| TachycardiaCardiac disorders | 1/27 | 0/11 |
| Event | Ruconest | Standard of Care |
|---|---|---|
| TransaminitisInvestigations | 6/27 | 0/11 |
| Fibrin D dimer increasedInvestigations | 5/27 | 1/11 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/27 | 2/11 |
| Blood lactate dehydrogenase incInvestigations | 4/27 | 1/11 |
| LeukocytosisBlood and lymphatic system disorders | 3/27 | 1/11 |
| NauseaGastrointestinal disorders | 3/27 | 0/11 |
| TachycardiaCardiac disorders | 2/27 | 1/11 |
| ConstipationGastrointestinal disorders | 1/27 | 1/11 |
| SepsisInfections and infestations | 1/27 | 1/11 |
| C-reactive protein increasedInvestigations | 2/27 | 1/11 |
Analyzed (FAS/ITT - Interim analysis/Overrunning analysis) in interim analysis phase: rhC1INH plus SOC \[n=23\]; SOC alone \[n=9\]. A subsequent (post hoc) analysis was conducted to include all 38 patients, overrunning analysis phase: rhC1INH plus SOC \[n=27\]; SOC alone \[n=11\].
| Age, Categorical(Participants) | Ruconest | Standard of Care | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 23 | 7 | 30 |
| >=65 years | 4 | 4 | 8 |
| Age, Continuous(years) | Ruconest | Standard of Care | Total |
|---|---|---|---|
| Mean | 55.93 ± 11.84 | 55.18 ± 8.99 | 55.55 ± 10.42 |
| Sex: Female, Male(Participants) | Ruconest | Standard of Care | Total |
|---|---|---|---|
| Female | 13 | 3 | 16 |
| Male | 14 | 8 | 22 |
| Race (NIH/OMB)(Participants) | Ruconest | Standard of Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 25 | 8 | 33 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Body Mass Index(kg/m^2) | Ruconest | Standard of Care | Total |
|---|---|---|---|
| Mean | 34.58 ± 6.07 | 30.54 ± 8.55 | 32.56 ± 7.31 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Sep 2021, 9 months.
Results were first posted in Feb 2024, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Conestat alfa